HIV Infections Clinical Trial
Official title:
Uridine Supplementation, Mitochondrial Function, and Glucose Metabolism in HIV
The purpose of this study is to determine whether uridine supplementation will improve insulin sensitivity and overall carbohydrate metabolism in HIV-positive subjects who are currently undergoing treatment with antiretroviral regimens containing stavudine or zidovudine and who have evidence of impaired mitochondrial function and insulin resistance.
Treatment of HIV infection with nucleoside analogue reverse transcriptase inhibitors (NRTIs)
has been associated with numerous toxicities that have been attributed to impaired
mitochondrial function secondary to a reduction in the levels of mitochondrial DNA (mtDNA).
Abnormalities in mitochondrial function have been implicated in the development of insulin
resistance in patients with HIV infection and have also been hypothesized to underlie many of
the pathophysiologic features of type 2 diabetes mellitus in non-HIV infected individuals.
Uridine, a pyrimidine nucleoside that plays an essential role in the synthesis of RNA and
other key physiologic processes, has been proposed as a therapy for NRTI-induced
mitochondrial dysfunction. Uridine supplementation protected bone marrow cells from the
toxicity of zidovudine, normalized the growth of neurons exposed to NRTIs, and abrogated
mitochondrial toxicity of NRTIs in HepG2 cells in vitro. A food supplement called
NucleomaxX®, extracted from the stem of sugar cane, raises plasma uridine concentrations to
levels known to prevent mitochondrial toxicity in vitro. In a recent case report, oral
administration of uridine, given in the form of NucleomaxX®, ameliorated the mitochondrial
toxicity caused by stavudine and led to improvements in myalgias and liver and muscle
enzymes, despite continuing treatment with stavudine. In a clinical study of 14 HIV-infected
patients treated with stavudine or zidovudine, NucleomaxX® led to improved hepatic
mitochondrial function as assessed by the 13C-methionine breath test.
We will perform a randomized double-blind placebo-controlled study in 20 HIV-positive
subjects who are currently undergoing treatment with antiretroviral regimens containing
stavudine or zidovudine and who have evidence of impaired mitochondrial function and insulin
resistance. Subjects will be hospitalized in the SFGH CTSI Clinical Research Center (CCRC)
for 6 days to undergo comprehensive metabolic studies. Subjects will then be randomized, in a
1:1 fashion, to receive either NucleomaxX® or placebo for two months, after which they will
repeat the 6-day CCRC-based assessments. This study is designed to test the hypothesis that,
in comparison to placebo, uridine supplementation will enhance mitochondrial function, and
this will be associated with concomitant improvements in glucose and lipid metabolism.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |